<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;ff=20230928 18 0724&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC- &amp;utm_source=Chrome<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;ff=20230928180724&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 9 月 28 日星期四 22:07:25 +0000</lastbuilddate><pubDate> Thu, 28 Sep 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>食物就是药物：美国心脏协会的总统建议</title><link/>https://pubmed.ncbi.nlm.nih.gov/37767686/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>不健康的饮食是美国实现健康人口的主要障碍。尽管人们对健康饮食的构成有相对清晰的认识，但大多数美国人并没有按照推荐的临床指南食用健康食品。大量的障碍，包括粮食和营养不安全、粮食的营销和广告方式、行为健康食品的获取和负担能力，以及关注眼前的挑战等。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 28 日。doi：10.1161/CIR.0000000000001182。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">不健康的饮食是美国实现健康人口的主要障碍。尽管人们对健康饮食的构成有相对清晰的认识，但大多数美国人并没有按照推荐的临床指南食用健康食品。大量的障碍，包括食品和营养不安全、食品的营销和广告方式、行为健康食品的获取和负担能力，以及关注即时满足与延迟满足等挑战，阻碍了许多美国人的健康饮食模式. 食物就是药物可以定义为与医疗保健部门协调提供健康食品资源以预防、管理或治疗特定的临床病症。尽管该领域前景广阔，但提供有力证据的设计的研究相对较少“食物即药物”干预措施与健康结果或健康成本之间的关联。需要做大量工作来创建更有力的证据，令人信服地证明不同类型“食物即药物”干预措施的有效性和成本效益。估计 90%美国每年 4.3 万亿美元的医疗保健费用用于慢性病的医疗保健。对于许多这些疾病，饮食是一个主要的风险因素，因此即使是适度的饮食也可能产生显着的改善影响。此总统建议提供食物即医学领域的现状概述以及新研究计划的路线图，该计划战略性地解决该领域的突出问题，同时优先考虑以人为本的设计方法，以实现患者的高参与度和持续的行为改变。理想情况下，这将在更广泛努力的背景下发生，以使用以健康公平为中心的方法来加强我们的粮食系统和相关政策支持改善健康的方式。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37767686/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37767686</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001182>10.1161/CIR.0000000000001182</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37767686</guid><pubDate> Thu, 28 Sep 2023 06:00:00 -0400</pubDate><dc:creator>凯文·G·沃尔普</dc:creator><dc:creator>塞思·伯科维茨</dc:creator><dc:creator>什里拉诉夏尔马</dc:creator><dc:creator>谢丽尔·安德森</dc:creator><dc:creator>拉普林斯·C·布鲁尔</dc:creator><dc:creator>米切尔·SV·埃尔金德</dc:creator><dc:creator>克里斯托弗·D·加德纳</dc:creator><dc:creator>朱莉·E·格维斯</dc:creator><dc:creator>罗伯特·哈林顿</dc:creator><dc:creator>马里奥·埃雷罗</dc:creator><dc:creator>艾丽丝·H·利希滕斯坦</dc:creator><dc:creator>马克·麦克莱伦</dc:creator><dc:creator>珍·缪斯</dc:creator><dc:creator>克里斯蒂娜·罗伯托</dc:creator><dc:creator>贾斯汀·PV·撒迦利亚</dc:creator><dc:creator>美国心脏协会</dc:creator><dc:date>2023-09-28</dc:date><dc:source>循环</dc:source><dc:title>食物就是药物：美国心脏协会的总统建议</dc:title><dc:identifier>下午：37767686</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001182</dc:identifier></item><item><title>答复：主动脉瓣关闭不全的心脏重塑</title><link/>https://pubmed.ncbi.nlm.nih.gov/37758444/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 3 日；82(14):e125.doi:10.1016/j.jacc.2023.07.022。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37758444/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37758444</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.022>10.1016/j.jacc.2023.07.022</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37758444</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>马安·马拉赫吉</dc:creator><dc:creator>德·T·阮</dc:creator><dc:creator>爱德华·格拉维斯</dc:creator><dc:creator>迪潘·J·沙阿</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>答复：主动脉瓣关闭不全的心脏重塑</dc:title><dc:identifier>下午：37758444</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.022</dc:identifier></item><item><title>主动脉瓣关闭不全的左心室重构</title><link/>https://pubmed.ncbi.nlm.nih.gov/37758443/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 3 日；82(14):e123.doi:10.1016/j.jacc.2023.06.049。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37758443/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37758443</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.049>10.1016/j.jacc.2023.06.049</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37758443</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>拉姆达斯·G·派</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>主动脉瓣关闭不全的左心室重构</dc:title><dc:identifier>下午：37758443</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.049</dc:identifier></item><item><title>二叶式主动脉瓣：一种不可忽视的异常现象</title><link/>https://pubmed.ncbi.nlm.nih.gov/37758442/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 3 日；82(14):e121.doi:10.1016/j.jacc.2023.06.050。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37758442/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37758442</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.050>10.1016/j.jacc.2023.06.050</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37758442</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>刘波</dc:creator><dc:creator>蒋宣</dc:creator><dc:creator>谷天祥</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>二叶式主动脉瓣：一种不可忽视的异常现象</dc:title><dc:identifier>下午：37758442</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.050</dc:identifier></item><item><title>耐用的机械循环支持：JACC 科学声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37758441/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>尽管 C 期心力衰竭 (HF) 患者的药物治疗取得了进展，但晚期 HF 患者的 5 年生存率 &lt;20%。耐用的左心室辅助装置 (dLVAD) 支持是晚期 HF 患者的重要治疗选择。 dLVAD 技术的创新降低了多种不良事件的风险，包括泵血栓形成、中风和出血。现在，患者 2 年平均生存率与心脏移植相似，而 5 年 dLVAD... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 3 日；82(14):1464-1481.doi:10.1016/j.jacc.2023.07.019。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">尽管 C 期心力衰竭 (HF) 患者的药物治疗取得了进展，但晚期 HF 患者的 5 年生存率 &lt;20%。耐用的左心室辅助装置 (dLVAD) 支持是晚期 HF 患者的重要治疗选择。 dLVAD 技术的创新降低了多种不良事件的风险，包括泵血栓形成、中风和出血。现在患者的 2 年平均生存率与心脏移植相似，5 年 dLVAD 生存率现已接近 60%。不幸的是，由于延迟将患者转诊至先进的心力衰竭中心、临床医生对当代 dLVAD 结局（包括生活质量的提高）了解不足，以及等待心脏移植的接受 dLVAD 支持的患者的优先级较低，dLVAD 治疗尚未得到更多采用。面对挑战，新型设备即将进入临床研究，其尺寸更小，允许进行侵入性较小的手术植入，并消除了经皮供电导线。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37758441/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37758441</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.019>10.1016/j.jacc.2023.07.019</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37758441</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>瑞安·特德福德</dc:creator><dc:creator>玛齐亚·利奇</dc:creator><dc:creator>安吉拉·洛茨</dc:creator><dc:creator>斯塔夫罗斯·G·德拉科斯</dc:creator><dc:creator>弗朗西斯·D·帕加尼</dc:creator><dc:creator>詹妮弗·考格</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>耐用的机械循环支持：JACC 科学声明</dc:title><dc:identifier>下午：37758441</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.019</dc:identifier></item><item><title>心血管试验中的重复事件：JACC 最先进的综述</title><link/>https://pubmed.ncbi.nlm.nih.gov/37758440/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>许多心血管疾病随机试验在患者随访期间重复发生非致命事件（例如住院治疗）；然而，将首次事件发生时间作为主要结局仍然是常见做法。我们探讨了包括重复事件在内的分析的价值事件。它们是否帮助我们了解治疗效果和总疾病负担？它们是否增强了统计能力？它们是否应该成为试验的主要分析？也可能很难选择各种...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 3 日；82(14):1445-1463.doi:10.1016/j.jacc.2023.07.024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">许多心血管疾病随机试验在患者随访期间重复发生非致命事件（例如住院治疗）；然而，将首次事件发生时间作为主要结局仍然是常见做法。我们探讨了包括重复事件在内的分析的价值它们是否帮助我们了解治疗效果和总疾病负担？它们是否增强了统计能力？它们是否应该成为试验的主要分析？在分析重复事件的各种统计方法中选择使用哪种也可能很困难，我们为每种方法的作用提供了非技术性指南。我们比较了重复事件的几种方法：林伟杨颖、负二项式、关节脆弱性、胜率和曲线下面积。我们说明了它们在 5 项大型心血管试验中的表现并将它们与首次事件发生时间分析进行比较。我们回顾了它们在最近发表的心力衰竭试验中的使用，并为它们在未来试验中的使用提出了建议。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37758440/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37758440</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.024>10.1016/j.jacc.2023.07.024</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37758440</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>约翰·格雷格森</dc:creator><dc:creator>格雷格·W·斯通</dc:creator><dc:creator>迪帕克·巴特</dc:creator><dc:creator>米尔顿·帕克</dc:creator><dc:creator>斯特凡·D·安克</dc:creator><dc:creator>科尔杜拉·泽勒</dc:creator><dc:creator>比约恩·雷德福斯</dc:creator><dc:creator>斯图尔特·J·波科克</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>心血管试验中的重复事件：JACC 最先进的综述</dc:title><dc:identifier>下午:37758440</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.024</dc:identifier></item><item><title>严重左心梗阻的混合姑息疗法具有多种用途：风险因素仍然阻碍最佳结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/37758439/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 3 日；82(14):1442-1444.doi:10.1016/j.jacc.2023.08.023。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37758439/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37758439</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.023>10.1016/j.jacc.2023.08.023</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37758439</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>乔纳森·J·罗马</dc:creator><dc:creator>迈克尔·L·奥伯恩</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>严重左心梗阻的混合姑息疗法具有多种用途：风险因素仍然阻碍最佳结果</dc:title><dc:identifier>下午:37758439</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.023</dc:identifier></item><item><title>严重左心梗阻婴儿混合姑息治疗后的结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/37758438/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>结论：对于患有严重左心梗阻的婴儿，混合姑息治疗后死亡率仍然很高。然而，混合姑息治疗可能有助于某些婴儿的双心室修复，而对于其他婴儿来说，可能会稳定预期的功能性单心室姑息治疗或初次移植。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 3 日；82(14):1427-1441.doi:10.1016/j.jacc.2023.07.020。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：混合姑息治疗（双侧肺动脉束带术，有或没有导管支架置入术）是严重左心梗阻婴儿的初始治疗策略，在进行后续手术之前起到姑息治疗的作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究旨在确定患者特征以及与接受混合姑息治疗的婴儿随后的结局相关的因素。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从 2005 年到 2019 年，先天性心脏病外科医生协会的严重左心梗阻队列中的 1,236 名前瞻性婴儿中的 214 名在 24 个机构中进行了混合姑息治疗。采用竞争风险方法进行多变量危险建模，以确定与结果相关的风险和因素。双心室修复、Fontan 手术、移植或死亡。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：70% 的婴儿（214 名婴儿中的 150 名）发现术前合并症（例如，早产、低出生体重、遗传综合征）。中位随访时间为 7 年，最长可达 17 年。总体 12 年生存率为 55 %。混合姑息治疗后 5 年，9% 进行了双心室修复，36% 进行了 Fontan 手术，12% 进行了移植，35% 在没有手术终点的情况下死亡，8% 在没有终点的情况下存活。与移植相关的因素是缺乏导管支架植入、年龄较大、心房间通讯缺失、主动脉根部较小、三尖瓣面积 z 值较大、左心室容积较大。与死亡相关的因素包括低出生体重、伴随遗传综合征、混合姑息治疗期间使用心肺转流术、中度至严重的三尖瓣关闭不全，升主动脉尺寸较小。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：对于患有严重左心梗阻的婴儿，混合姑息治疗后死亡率仍然很高。然而，混合姑息治疗可能有助于某些婴儿的双心室修复，而对于其他婴儿来说，可能会稳定预期的功能性单心室姑息治疗或初次移植。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37758438/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37758438</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.020>10.1016/j.jacc.2023.07.020</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37758438</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>麦迪逊·B·阿尔戈</dc:creator><dc:creator>大卫·J·巴伦</dc:creator><dc:creator>皮鲁兹·埃格特萨迪</dc:creator><dc:creator>坎埃里巴坎</dc:creator><dc:creator>威廉姆斯·M·德坎普利</dc:creator><dc:creator>巴哈尔丁·阿尔苏菲</dc:creator><dc:creator>本庄修美</dc:creator><dc:creator>杰弗里·P·雅各布斯</dc:creator><dc:creator>塔里尼·帕拉马南坦</dc:creator><dc:creator>玛哈·拉赫曼</dc:creator><dc:creator>琳达·M·兰伯特</dc:creator><dc:creator>阿努莎·杰加西斯瓦兰</dc:creator><dc:creator>塞尔吉奥·卡里略</dc:creator><dc:creator>S阿迪尔·侯赛因</dc:creator><dc:creator>卡蒂克·拉马克里希南</dc:creator><dc:creator>克里斯托弗·卡尔达隆</dc:creator><dc:creator>塔拉·卡拉姆卢</dc:creator><dc:creator>詹妮弗·纳尔逊</dc:creator><dc:creator>切尔西·曼尼</dc:creator><dc:creator>詹妮弗·C·罗马诺</dc:creator><dc:creator>约瑟夫·W·图雷克</dc:creator><dc:creator>尤金·H·布莱克斯通</dc:creator><dc:creator>马克·E·加兰托维奇</dc:creator><dc:creator>詹姆斯·柯克林</dc:creator><dc:creator>迈克尔·E·米切尔</dc:creator><dc:creator>布赖恩·W·麦克兰德尔</dc:creator><dc:creator>先天性心脏病外科医生协会严重左心梗阻工作组</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>严重左心梗阻婴儿混合姑息治疗后的结果</dc:title><dc:identifier>下午：37758438</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.020</dc:identifier></item><item><title>颈动脉夹层血管危险因素的基因剖析：压力下</title><link/>https://pubmed.ncbi.nlm.nih.gov/37758437/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 3 日；82(14):1424-1426.doi:10.1016/j.jacc.2023.08.011。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37758437/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37758437</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.011>10.1016/j.jacc.2023.08.011</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37758437</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>蒂内·德巴克尔</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>颈动脉夹层血管危险因素的基因剖析：压力下</dc:title><dc:identifier>下午：37758437</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.011</dc:identifier></item><item><title>关于血管危险因素与颈动脉夹层关系的遗传学见解</title><link/>https://pubmed.ncbi.nlm.nih.gov/37758436/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>结论：这些结果支持高血压与 CeAD 风险增加和复发之间存在因果关系，并为使用 β 受体阻滞剂降低 CeAD 风险提供了遗传证据。这可能为 CeAD 的二级预防策略和试验设计提供信息。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 3 日；82(14):1411-1423.doi:10.1016/j.jacc.2023.07.021。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：血管危险因素与颈动脉夹层（CeADs）之间的关联仍然存在争议，颈动脉夹层是年轻人缺血性卒中（IS）的主要原因。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究旨在探讨血管危险因素与 CeAD 风险和复发的因果关系，并将其与非 CeAD IS 的关系进行比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：本研究采用 2 个样本孟德尔随机化分析来探讨血压 (BP)、血脂水平、2 型糖尿病、腰臀比、吸烟和体重指数与 CeAD 和非 CeAD IS 的关系。为了模拟最常用的降压药物的效果，本研究构建了遗传代理并测试了它们与 CeAD 和非 CeAD IS 的关联。在分析 CeAD 患者时，研究人员研究了血管风险加权遗传风险评分之间的关​​联因素以及多次或早期复发性夹层的风险。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：基因决定的较高收缩压（OR：1.51；95% CI：1.32-1.72）和舒张压（OR：2.40；95% CI：1.92-3.00）会增加 CeAD 的风险（P &lt; 0.0001）。体重指数与较低的 CeAD 风险相关性不一致。β 受体阻滞剂效应的遗传代理与较低的 CeAD 风险相关（OR：0.65；95% CI：0.50-0.85），而钙通道阻滞剂则与较低的 CeAD 风险相关。非 CeAD IS 的风险较低（OR：0.75；95% CI：0.63-0.90）。收缩压和舒张压的加权遗传风险评分与多次或早期复发 CeAD 的风险增加相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这些结果支持高血压与 CeAD 风险增加和复发之间存在因果关系，并为使用 β 受体阻滞剂降低 CeAD 风险提供了遗传证据。这可能为 CeAD 的二级预防策略和试验设计提供信息。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37758436/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37758436</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.021>10.1016/j.jacc.2023.07.021</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37758436</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>昆汀·勒格兰德</dc:creator><dc:creator>莱斯利·埃克·费雷拉</dc:creator><dc:creator>蒂娜·美卓</dc:creator><dc:creator>萨布丽娜·席林</dc:creator><dc:creator>图尔古特·塔特利苏马克</dc:creator><dc:creator>卡斯帕·格隆德-金斯巴赫</dc:creator><dc:creator>斯特凡·T·恩格尔特</dc:creator><dc:creator>菲利普·莱勒</dc:creator><dc:creator>詹妮弗·J·马杰西克</dc:creator><dc:creator>布拉德福德·B·沃勒尔</dc:creator><dc:creator>安德鲁·M·萨瑟兰</dc:creator><dc:creator>休·S·马库斯</dc:creator><dc:creator>马克·拉斯罗普</dc:creator><dc:creator>文森特·泰斯</dc:creator><dc:creator>迪迪埃·莱斯</dc:creator><dc:creator>菲利普·阿穆耶尔</dc:creator><dc:creator>让·达隆格维尔</dc:creator><dc:creator>马丁·迪奇甘斯</dc:creator><dc:creator>亚历山德罗·佩齐尼</dc:creator><dc:creator>安娜贝尔萨诺</dc:creator><dc:creator>穆拉利达兰·萨尔古鲁普雷姆拉吉</dc:creator><dc:creator>斯蒂芬妮·黛贝特</dc:creator><dc:creator>CADISP联盟</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>关于血管危险因素与颈动脉夹层关系的遗传学见解</dc:title><dc:identifier>下午：37758436</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.021</dc:identifier></item><item><title>妊娠期瓣膜性心脏病的风险评估：时机已到的想法</title><link/>https://pubmed.ncbi.nlm.nih.gov/37758435/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 3 日；82(14):1407-1410.doi:10.1016/j.jacc.2023.08.022。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37758435/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37758435</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.022>10.1016/j.jacc.2023.08.022</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37758435</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>加里玛·夏尔马</dc:creator><dc:creator>阿迪亚·梅塔</dc:creator><dc:creator>南迪塔·S·斯科特</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>妊娠期瓣膜性心脏病的风险评估：时机已到的想法</dc:title><dc:identifier>下午：37758435</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.022</dc:identifier></item><item><title>瓣膜性心脏病孕妇心脏事件风险分层的验证</title><link/>https://pubmed.ncbi.nlm.nih.gov/37758434/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>结论：在 VHD 妊娠患者中，DEVI 和 CARPREG-II 评分在一系列概率上表现出良好的区分能力和临床实用性。DEVI 评分显示预测概率和观察到的事件之间具有更好的一致性。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 3 日；82(14):1395-1406.doi:10.1016/j.jacc.2023.07.023。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：大多数针对妊娠心脏病患者的风险分层工具是在高收入国家和主要患有先天性心脏病的人群中开发的，因此可能无法推广到瓣膜性心脏病（VHD）患者。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究的目的是验证和建立 2 种风险分层工具——DEVI（VHD 特异性工具）和 CARPREG-II——在预测妊娠 VHD 患者心脏不良事件方面的临床效用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们进行了一项队列研究，涉及 2019 年 1 月至 2022 年 4 月入住中等收入环境中的三级中心的连续妊娠并发 VHD 的患者。使用 DEVI 和 CARPREG-II 模型计算不良复合心脏事件的个体风险。通过辨别和校准特征进行评估。临床效用通过决策曲线分析进行评估。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 577 例符合条件的妊娠中，69 例 (12.1%) 经历了综合结果的组成部分。大多数 (94.7%) 具有风湿病因，其中二尖瓣反流是主要病变 (48.2%)。接受者操作特征下的面积DEVI 的曲线为 0.884 (95% CI: 0.844-0.923)，CARPREG-II 模型的曲线为 0.808 (95% CI: 0.753-0.863)。校准图表明 DEVI 评分在较高概率下高估了风险，而 CARPREG-II 评分高估了两个极端的风险，低估了中等概率的风险。决策曲线分析表明，这两种模型在 10% 到 50% 之间的预测概率阈值中都是有用的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在 VHD 妊娠患者中，DEVI 和 CARPREG-II 评分在一系列概率上表现出良好的区分能力和临床实用性。DEVI 评分显示预测概率和观察到的事件之间具有更好的一致性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37758434/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37758434</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.023>10.1016/j.jacc.2023.07.023</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37758434</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>斯瓦拉吉·南迪尼·潘德</dc:creator><dc:creator>J·亚瓦娜·苏里亚</dc:creator><dc:creator>萨吉特·甘纳巴蒂</dc:creator><dc:creator>阿吉斯·阿南塔克里希纳·皮莱</dc:creator><dc:creator>桑托什·萨蒂什</dc:creator><dc:creator>尼维迪塔·蒙达尔</dc:creator><dc:creator>KT 哈里钱德拉·库马尔</dc:creator><dc:creator>坎迪斯·西尔弗塞德斯</dc:creator><dc:creator>萧志明</dc:creator><dc:creator>罗汉·德索萨</dc:creator><dc:creator>安尼什·凯帕纳塞里尔</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>瓣膜性心脏病孕妇心脏事件风险分层的验证</dc:title><dc:identifier>下午:37758434</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.023</dc:identifier></item><item><title>老年人初级预防的前景</title><link/>https://pubmed.ncbi.nlm.nih.gov/37758433/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 3 日；82(14):1392-1394.doi:10.1016/j.jacc.2023.08.005。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37758433/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37758433</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.005>10.1016/j.jacc.2023.08.005</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37758433</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>萨菲·乌·汗</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>老年人初级预防的前景</dc:title><dc:identifier>下午：37758433</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.005</dc:identifier></item><item><title>通过降脂疗法降低 LDL-C，用于老年人主要血管事件的一级预防</title><link/>https://pubmed.ncbi.nlm.nih.gov/37758432/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>结论：我们的研究支持降低 LDL 胆固醇对于年龄≥70 岁的个体主要血管事件的一级预防具有相对的临床益处，与年龄 &lt;70 岁的个体相似。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 3 日；82(14):1381-1391.doi:10.1016/j.jacc.2023.07.027。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：在初级预防试验中，通过降脂疗法降低低密度脂蛋白 (LDL) 胆固醇已被一致证明可以降低心血管疾病的风险，其中大多数个体年龄&lt;70 岁。然而，对于老年人来说，证据是不太清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：在这项研究中，作者试图比较丹麦全国队列中老年人和年轻人通过降脂疗法降低 LDL 胆固醇对心血管疾病一级预防的临床效果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们纳入了年龄≥50岁、从2008年1月1日至2017年10月31日开始降脂治疗、无动脉粥样硬化性心血管疾病史、有基线和一年内低密度脂蛋白胆固醇测量的个体。与年轻个体（&lt;70 岁）相比，我们通过 LDL 胆固醇每降低 1 mmol/L 的 HR 来评估老年个体（≥ 70 岁）发生主要血管事件的相关风险。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：对于 16,035 名老年人和 49,155 名年轻人，LDL 胆固醇的中位数降低为 1.7 mmol/L。老年人 LDL 胆固醇每降低 1 mmol/L，主要血管事件的风险就会降低 23% 显着相关（ HR：0.77；95% CI：0.71-0.83），与年轻个体相同（HR：0.76；95% CI：0.71-0.80；差异 P 值 = 0.79）。在所有二次分析中都观察到类似的结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的研究支持降低 LDL 胆固醇对于年龄≥70 岁的个体主要血管事件的一级预防具有相对的临床益处，与年龄 &lt;70 岁的个体相似。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37758432/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37758432</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.027>10.1016/j.jacc.2023.07.027</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37758432</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>尼克拉斯·沃姆·安德森</dc:creator><dc:creator>朱莉娅·玉米</dc:creator><dc:creator>蒂内·洛夫索·多尔曼</dc:creator><dc:creator>麦兹·梅尔比</dc:creator><dc:creator>简·沃尔法特</dc:creator><dc:creator>玛丽·隆德</dc:creator><dc:date>2023-09-27</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>通过降脂疗法降低 LDL-C，用于老年人主要血管事件的一级预防</dc:title><dc:identifier>下午：37758432</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.027</dc:identifier></item><item><title>患有先天性心脏病的成人的获得性心血管疾病</title><link/>https://pubmed.ncbi.nlm.nih.gov/37758198/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>近几十年来，先天性心脏病患者的手术修复成功率和预期寿命急剧增加。由于诊断、治疗和后续护理的进步，越来越多的先天性心脏病患者步入高龄。在他们的一生中接触心血管危险因素正在改变成人先天性心脏病 (ACHD) 的前景和后期临床轨迹。他们的疾病负担是...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 27:ehad570.doi: 10.1093/eurheartj/ehad570. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">近几十年来，先天性心脏病患者的手术修复成功率和预期寿命急剧增加。由于诊断、治疗和后续护理的进步，越来越多的先天性心脏病患者步入高龄。在他们的一生中接触心血管危险因素正在改变成人先天性心脏病 (ACHD) 的前景和后期临床轨迹。他们的疾病负担正在从先天性转向后天性，主要是动脉粥样硬化性心血管疾病 (ASCVD)，并带来令人担忧的后果。此外， ACHD 的复杂背景常常限制全科医生或成人心脏病专家采取适当的预防策略。目前还没有针对 ACHD 患者获得性心脏病预防和管理的综合指南，因为欧洲心脏病学会尚未涵盖该主题（ ESC) 心血管疾病预防指南或 ESC ACHD 管理指南。本文件对 ACHD 患者获得性心脏病进行了最新概述，并为 ACHD 专家和非 ACHD 提供了 ASCVD 预防指南目的是提供一份临床共识声明，以促进在这一不断增长的心血管人群中以实用且易于遵循的方式制定可持续战略，以预防 ASCVD，从而减轻他们的心血管负担。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37758198/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37758198</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad570>10.1093/eurheartj/ehad570</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37758198</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>玛格丽塔·布里达</dc:creator><dc:creator>萨尔瓦多·德·罗莎</dc:creator><dc:creator>安托万·勒让德</dc:creator><dc:creator>马加莉·拉杜塞尔</dc:creator><dc:creator>劳拉·多斯·苏比拉</dc:creator><dc:creator>吉安卡洛·斯科格纳米利奥</dc:creator><dc:creator>卡洛·迪·马里奥</dc:creator><dc:creator>朱利安·鲁斯-海塞林克</dc:creator><dc:creator>伊娃·古森斯</dc:creator><dc:creator>格哈德·迪勒</dc:creator><dc:creator>迈克尔·加佐利斯</dc:creator><dc:date>2023-09-27</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>患有先天性心脏病的成人的获得性心血管疾病</dc:title><dc:identifier>下午:37758198</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad570</dc:identifier></item><item><title>自合性对整个表型谱中常见疾病风险的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37757828/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description>自合性与罕见的孟德尔疾病和临床相关的数量性状有关。我们在英国生物银行的《基因与健康》（n = 23,978 名英国南亚人）中研究了纯合性运行中基因组的分数 (F(ROH)) 与常见疾病之间的关联(n = 397,184) 和 23andMe。我们表明，将分析限制在第一代堂兄弟姐妹的后代是减少由于 F(ROH) 的社会/环境相关性而造成的混杂的有效方法。在 G&amp;H+UK 的这一组中... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 20 日：S0092-8674(23)00918-2. doi: 10.1016/j.cell.2023.08.028. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">自合性与罕见的孟德尔疾病和临床<sub>相关</sub>的数量性状有关。我们在基因与健康（n = 23,978 英国南亚人）、英国生物银行（n = 397,184) 和 23andMe。我们表明，将分析限制在第一代堂兄弟姐妹的后代是减少由于 F <sub>ROH</sub>的社会/环境相关性而造成的混杂的有效方法。在 G&amp;H+UK 生物银行的这一组中，我们发现整个实验范围F <sub>ROH</sub>与 12 种常见疾病之间存在显着关联。我们通过 23andMe 中的兄弟姐妹内分析复制了与 2 型糖尿病 (T2D) 和创伤后应激障碍的关联（中位数 n = 480,282）。我们估计由于血缘关系导致的自合性占 5 %- 18% 的英国巴基斯坦人中的 T2D 病例。我们的工作强调了对常见疾病存在广泛的非累加性遗传效应的可能性，并对全球近亲率高的人群具有重要意义。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37757828/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37757828</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.028>10.1016/j.cell.2023.08.028</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37757828</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator>丹尼尔·马拉夫斯基</dc:creator><dc:creator>伊娃·范·沃尔里</dc:creator><dc:creator>本杰明·雅各布斯</dc:creator><dc:creator>丁香兴</dc:creator><dc:creator>秦勤黄</dc:creator><dc:creator>阿塔夫·H·萨比尔</dc:creator><dc:creator>萨迪亚·拉赫曼</dc:creator><dc:creator>萨吉拉·马利克·谢里夫</dc:creator><dc:creator>阿桑·汗</dc:creator><dc:creator>马萨·乌米切维奇·米尔科夫</dc:creator><dc:creator>23andMe研究团队</dc:creator><dc:creator>基因与健康研究团队</dc:creator><dc:creator>桑原博之</dc:creator><dc:creator>高鑫</dc:creator><dc:creator>福赞·阿尔库拉亚</dc:creator><dc:creator>丹妮尔·波斯图玛</dc:creator><dc:creator>威廉·G·纽曼</dc:creator><dc:creator>克里斯托弗·J·格里菲斯</dc:creator><dc:creator>罗希尼·马图尔</dc:creator><dc:creator>大卫·A·范·希尔</dc:creator><dc:creator>莎拉·芬纳</dc:creator><dc:creator>贾里德·奥康奈尔</dc:creator><dc:creator>希拉里·C·马丁</dc:creator><dc:date>2023-09-27</dc:date><dc:source>细胞</dc:source><dc:title>自合性对整个表型谱中常见疾病风险的影响</dc:title><dc:identifier>下午：37757828</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.028</dc:identifier></item><item><title>经皮冠状动脉介入治疗后吸烟与心血管结局：一项韩国研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37757448/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230928180724&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Smoking is associated with a higher risk of adverse outcomes in patients undergoing PCI. Quitters after PCI with &lt;20 PYs were associated with a risk comparable with that of non-smokers. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 26:ehad616. doi: 10.1093/eurheartj/ehad616. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: The authors investigated the impact of smoking and its cessation after percutaneous coronary intervention (PCI) on cardiovascular outcomes. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Using a nationwide database from the Korean National Health Insurance System, 74 471 patients undergoing PCI between 2009 and 2016 were classified as non-, ex-, or current smokers, depending on smoking status at the first health check-up within 1 year after PCI. The primary outcome was major adverse cardiovascular and cerebrovascular event (MACCE), a composite of all-cause death, myocardial infarction, coronary revascularization, and stroke. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: During 4.0 years of follow-up, current smokers had a 19.8% higher rate of MACCE than non-smokers [adjusted hazard ratio (aHR) 1.198; 95% confidence interval (CI) 1.137-1.263], and ex-smokers tended to have a comparable rate with that of non-smokers (aHR 1.036; 95% CI .992-1.081). For 31 887 patients with both pre- and post-PCI health check-up data, the effects of smoking cessation were analysed. Among quitters who stopped smoking after PCI, quitters with cumulative smoking exposure of &lt;20 pack-years (PYs) tended to have a comparable rate of MACCE with that of persistent non-smokers. However, the rate in quitters with cumulative exposure of ≥20 PYs was comparable with that of persistent smokers [aHR (95% CI) for &lt;10 PY, 1.182 (.971-1.438); 10-20 PYs 1.114 (.963-1.290); 20-30 PYs 1.206 (1.054-1.380); ≥ 30 PYs 1.227 (1.113-1.352); persistent smokers 1.223 (1.126-1.328), compared with persistent non-smokers, respectively, P for interaction &lt;.001]. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Smoking is associated with a higher risk of adverse outcomes in patients undergoing PCI. Quitters after PCI with &lt;20 PYs were associated with a risk comparable with that of non-smokers.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37757448/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37757448</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad616>10.1093/eurheartj/ehad616</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37757448</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator> You-Jeong Ki</dc:creator><dc:creator> Kyungdo Han</dc:creator><dc:creator> Hyo-Soo Kim</dc:creator><dc:creator> Jung-Kyu Han</dc:creator><dc:date> 2023-09-27</dc:date><dc:source> European heart journal</dc:source><dc:title> Smoking and cardiovascular outcomes after percutaneous coronary intervention: a Korean study</dc:title><dc:identifier> pmid:37757448</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad616</dc:identifier></item><item><title> The Role of Posterior Wall Isolation in Catheter Ablation for Persistent Atrial Fibrillation and Systolic Heart Failure: A Secondary Analysis of a Randomized Clinical Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37755920/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928180724&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS AND RELEVANCE: The results of this study indicate that addition of PWI to PVI did not improve freedom from arrhythmia recurrence or recovery of LVEF in patients with persistent AF and symptomatic HFrEF. Catheter ablation was associated with significant improvements in systolic function, irrespective of ablation strategy used. These results caution against the routine inclusion of PWI in patients with HFrEF undergoing first-time catheter ablation for persistent AF. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Sep 27. doi: 10.1001/jamacardio.2023.3208. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> IMPORTANCE: Catheter ablation for patients with atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF) is associated with improved left ventricular ejection fraction (LVEF) and survival compared with medical therapy. Nonrandomized studies have reported improved success with posterior wall isolation (PWI). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To determine the impact of pulmonary vein isolation (PVI) with PWI vs PVI alone on outcomes in patients with HFrEF. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESIGN, SETTING, AND PARTICIPANTS: This was an ad hoc secondary analysis of the CAPLA trial, a multicenter, prospective, randomized control trial that involved 11 centers in 3 countries (Australia, Canada, and UK). CAPLA featured 338 patients with persistent AF randomized to either PVI plusPWI or PVI alone. This substudy included patients in the original CAPLA study who had symptomatic HFrEF (LVEF &lt;50% and New York Heart Association class ≥II). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTERVENTIONS: Pulmonary vein isolation with PWI vs PVI alone. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOMES AND MEASURES: The primary end point was freedom from any documented atrial arrhythmia greater than 30 seconds, after a single ablation procedure, without the use of antiarrhythmic drug (AAD) therapy at 12 months. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: A total of 98 patients with persistent AF and symptomatic HFrEF were identified (mean [SD] age, 62.1 [9.8] years; 79.5% men; and mean [SD] LVEF at baseline, 34.6% [7.9%]). After 12 months, 58.7% of patients with PVI plus PWI were free from recurrent atrial arrhythmia without the use of AAD therapy vs 61.5% with PVI alone (hazard ratio, 1.02; 95% CI, 0.54-1.91; P = .96). There were no significant differences in freedom from atrial arrhythmia with or without AAD therapy after multiple procedures (PVI plus PWI vs PVI alone, 60.9% vs 65.4%; P = .73) or AF burden (median, 0% in both groups; P = .78). Mean LVEF improved substantially in PVI plus PWI (∆ LVEF, 19.3% [13.0%; P &lt; .01) and PVI alone (18.2% [14.1%; P &lt; .01), with no difference between groups (P = .71). Normalization of LV function occurred in 65.2% of patients in the PVI plus PWI group and 50.0% of patients with PVI alone (P = .13). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS AND RELEVANCE: The results of this study indicate that addition of PWI to PVI did not improve freedom from arrhythmia recurrence or recovery of LVEF in patients with persistent AF and symptomatic HFrEF. Catheter ablation was associated with significant improvements in systolic function, irrespective of ablation strategy used. These results caution against the routine inclusion of PWI in patients with HFrEF undergoing first-time catheter ablation for persistent AF. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> TRIAL REGISTRATION: http://anzctr.org.au Identifier: ACTRN12616001436460.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37755920/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37755920</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.3208>10.1001/jamacardio.2023.3208</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37755920</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Jeremy William</dc:creator><dc:creator> David Chieng</dc:creator><dc:creator> Hariharan Sugumar</dc:creator><dc:creator> Liang-Han Ling</dc:creator><dc:creator> Louise Segan</dc:creator><dc:creator> Rose Crowley</dc:creator><dc:creator> Ahmed Al-Kaisey</dc:creator><dc:creator> Joshua Hawson</dc:creator><dc:creator> Sandeep Prabhu</dc:creator><dc:creator> Aleksandr Voskoboinik</dc:creator><dc:creator> Geoffrey Wong</dc:creator><dc:creator> Joseph B Morton</dc:creator><dc:creator> Geoffrey Lee</dc:creator><dc:creator> Alex J McLellan</dc:creator><dc:creator> Michael Wong</dc:creator><dc:creator> Rajeev K Pathak</dc:creator><dc:creator> Laurence Sterns</dc:creator><dc:creator> Matthew Ginks</dc:creator><dc:creator> Christopher M Reid</dc:creator><dc:creator> Prashanthan Sanders</dc:creator><dc:creator> Jonathan M Kalman</dc:creator><dc:creator> Peter M Kistler</dc:creator><dc:date> 2023-09-27</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> The Role of Posterior Wall Isolation in Catheter Ablation for Persistent Atrial Fibrillation and Systolic Heart Failure: A Secondary Analysis of a Randomized Clinical Trial</dc:title><dc:identifier> pmid:37755920</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3208</dc:identifier></item><item><title> Economic Evaluation of Angiotensin-Neprilysin Inhibitors Across Ejection Fractions</title><link/> https://pubmed.ncbi.nlm.nih.gov/37755820/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928180724&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Sep 27. doi: 10.1001/jamacardio.2023.3223. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37755820/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37755820</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.3223>10.1001/jamacardio.2023.3223</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37755820</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Laura P Cohen</dc:creator><dc:creator> Brandon K Bellows</dc:creator><dc:date> 2023-09-27</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Economic Evaluation of Angiotensin-Neprilysin Inhibitors Across Ejection Fractions</dc:title><dc:identifier> pmid:37755820</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3223</dc:identifier></item><item><title> Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management</title><link/> https://pubmed.ncbi.nlm.nih.gov/37755814/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928180724&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS AND RELEVANCE: Cost-effectiveness modeling provided an ICER for treatment with sacubitril-valsartan vs RASis consistent with high economic value for patients with reduced and mildly reduced EFs (≤50%) and at least intermediate value at the current undiscounted wholesale acquisition cost price at an EF of 60% or less. Treatment was more cost-effective at lower EF ranges. These findings may have implications for coverage decisions and value assessments in contemporary clinical practice... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Sep 27. doi: 10.1001/jamacardio.2023.3216. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> IMPORTANCE: The US Food and Drug Administration expanded labeling of sacubitril-valsartan from the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (EF) to all patients with HF, noting the greatest benefits in those with below-normal EF. However, the upper bound of below normal is not clearly defined, and value determinations across a broader EF range are unknown. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To estimate the cost-effectiveness of sacubitril-valsartan vs renin-angiotensin system inhibitors (RASis) across various upper-level cutoffs of EF. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation included participant-level data from the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and the PARAGON-HF (Prospective Comparison of ARNi with ARB Global Outcomes in HF With Preserved Ejection Fraction) trials. PARADIGM-HF was conducted between 2009 and 2014, PARAGON-HF was conducted between 2014 and 2019, and this analysis was conducted between 2021 and 2023. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOMES AND MEASURES: A 5-state Markov model used risk reductions for all-cause mortality and HF hospitalization from PARADIGM-HF and PARAGON-HF. Quality-of-life differences were estimated from EuroQol-5D scores. Hospitalization and medication costs were obtained from published national sources; the wholesale acquisition cost of sacubitril-valsartan was $7092 per year. Risk estimates and treatment effects were generated in consecutive 5% EF increments up to 60% and applied to an EF distribution of US patients with HF from the Get With the Guidelines-Heart Failure registry. The base case included a lifetime horizon from a health care sector perspective. Incremental cost-effectiveness ratios (ICERs) were estimated at EFs of 60% or less (base case) and at various upper-level EF cutoffs. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Among 13 264 total patients whose data were analyzed, for those with EFs of 60% or less, sacubitril-valsartan was projected to add 0.53 quality-adjusted life-years (QALYs) at an incremental lifetime cost of $40 892 compared with RASi, yielding an ICER of $76 852 per QALY. In a probabilistic sensitivity analysis, 95% of the values of the ICER occurred between $71 516 and $82 970 per QALY. Among patients with chronic HF and an EF of 60% or less, treatment with sacubitril-valsartan vs RASis would be at least of economic intermediate value (ICER &lt;$180 000 per QALY) at a sacubitril-valsartan cost of $10 242 or less per year, of high economic value (ICER &lt;$60 000 per QALY) at a cost of $3673 or less per year, and cost-saving at a cost of $338 or less per year. The ICERs were $67 331 per QALY, $59 614 per QALY, and $56 786 per QALY at EFs of 55% or less, 50% or less, and 45% or less, respectively. Treatment with sacubitril-valsartan in only those with EFs of 45% or greater (up to ≤60%) yielded an ICER of $127 172 per QALY gained; treatment was more cost-effective in those at the lower end of this range (ICER of $100 388 per QALY gained for those with EFs of 45%-55%; ICER of $84 291 per QALY gained for those with EFs of 45%-50%). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS AND RELEVANCE: Cost-effectiveness modeling provided an ICER for treatment with sacubitril-valsartan vs RASis consistent with high economic value for patients with reduced and mildly reduced EFs (≤50%) and at least intermediate value at the current undiscounted wholesale acquisition cost price at an EF of 60% or less. Treatment was more cost-effective at lower EF ranges. These findings may have implications for coverage decisions and value assessments in contemporary clinical practice guidelines.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37755814/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37755814</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.3216>10.1001/jamacardio.2023.3216</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37755814</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Ankeet S Bhatt</dc:creator><dc:creator> Muthiah Vaduganathan</dc:creator><dc:creator> Brian L Claggett</dc:creator><dc:creator> Gregg C Fonarow</dc:creator><dc:creator> Milton Packer</dc:creator><dc:creator> Marc A Pfeffer</dc:creator><dc:creator> Sanjiv J Shah</dc:creator><dc:creator> Xian Shen</dc:creator><dc:creator> Joaquim Cristino</dc:creator><dc:creator> John JV McMurray</dc:creator><dc:creator> Scott D Solomon</dc:creator><dc:creator> Thomas A Gaziano</dc:creator><dc:date> 2023-09-27</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management</dc:title><dc:identifier> pmid:37755814</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3216</dc:identifier></item><item><title> Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020</title><link/> https://pubmed.ncbi.nlm.nih.gov/37755728/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928180724&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS AND RELEVANCE: This cohort study found that CRM multimorbidity is increasingly common and undertreated among US adults, highlighting the importance of collaborative and comprehensive management strategies. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Sep 27. doi: 10.1001/jamacardio.2023.3241. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> IMPORTANCE: Individually, cardiac, renal, and metabolic (CRM) conditions are common and leading causes of death, disability, and health care-associated costs. However, the frequency with which CRM conditions coexist has not been comprehensively characterized to date. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To examine the prevalence and overlap of CRM conditions among US adults currently and over time. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESIGN, SETTING, AND PARTICIPANTS: To establish prevalence of CRM conditions, nationally representative, serial cross-sectional data included in the January 2015 through March 2020 National Health and Nutrition Examination Survey (NHANES) were evaluated in this cohort study. To assess temporal trends in CRM overlap, NHANES data between 1999-2002 and 2015-2020 were compared. Data on 11 607 nonpregnant US adults (≥20 years) were included. Data analysis occurred between November 10, 2020, and November 23, 2022. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOMES AND MEASURES: Proportion of participants with CRM conditions, overall and stratified by age, defined as cardiovascular disease (CVD), chronic kidney disease (CKD), type 2 diabetes (T2D), or all 3. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: From 2015 through March 2020, of 11 607 US adults included in the analysis (mean [SE] age, 48.5 [0.4] years; 51.0% women), 26.3% had at least 1 CRM condition, 8.0% had at least 2 CRM conditions, and 1.5% had 3 CRM conditions. Overall, CKD plus T2D was the most common CRM dyad (3.2%), followed by CVD plus T2D (1.7%) and CVD plus CKD (1.6%). Participants with higher CRM comorbidity burden were more likely to be older and male. Among participants aged 65 years or older, 33.6% had 1 CRM condition, 17.1% had 2 CRM conditions, and 5.0% had 3 CRM conditions. Within this subset, CKD plus T2D (7.3%) was most common, followed by CVD plus CKD (6.0%) and CVD plus T2D (3.8%). The CRM comorbidity burden was disproportionately high among participants reporting non-Hispanic Black race or ethnicity, unemployment, low socioeconomic status, and no high school degree. Among participants with 3 CRM conditions, nearly one-third (30.5%) did not report statin use, and only 4.8% and 3.0% used glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, respectively. Between 1999 and 2020, the proportion of US adults with multiple CRM conditions increased significantly (from 5.3% to 8.0%; P &lt; .001 for trend), as did the proportion having all 3 CRM conditions (0.7% to 1.5%; P &lt; .001 for trend). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS AND RELEVANCE: This cohort study found that CRM multimorbidity is increasingly common and undertreated among US adults, highlighting the importance of collaborative and comprehensive management strategies.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37755728/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928180724&v=2.17.9.post6+86293ac">37755728</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.3241>10.1001/jamacardio.2023.3241</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37755728</guid><pubDate> Wed, 27 Sep 2023 06:00:00 -0400</pubDate><dc:creator> John W Ostrominski</dc:creator><dc:creator> Suzanne V Arnold</dc:creator><dc:creator> Javed Butler</dc:creator><dc:creator> Gregg C Fonarow</dc:creator><dc:creator> Jamie S Hirsch</dc:creator><dc:creator> Swetha R Palli</dc:creator><dc:creator> Bonnie MK Donato</dc:creator><dc:creator> Christina M Parrinello</dc:creator><dc:creator> Thomas O&#39;Connell</dc:creator><dc:creator> Eric B Collins</dc:creator><dc:creator> Jonathan J Woolley</dc:creator><dc:creator> Mikhail N Kosiborod</dc:creator><dc:creator> Muthiah Vaduganathan</dc:creator><dc:date> 2023-09-27</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020</dc:title><dc:identifier> pmid:37755728</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3241</dc:identifier></item></channel></rss>